ITMI20021169A1 - Procedimento per incapsulare una sostanza attiva - Google Patents

Procedimento per incapsulare una sostanza attiva

Info

Publication number
ITMI20021169A1
ITMI20021169A1 IT2002MI001169A ITMI20021169A ITMI20021169A1 IT MI20021169 A1 ITMI20021169 A1 IT MI20021169A1 IT 2002MI001169 A IT2002MI001169 A IT 2002MI001169A IT MI20021169 A ITMI20021169 A IT MI20021169A IT MI20021169 A1 ITMI20021169 A1 IT MI20021169A1
Authority
IT
Italy
Prior art keywords
active substance
encapsulating
procedure
inter
coating
Prior art date
Application number
IT2002MI001169A
Other languages
English (en)
Inventor
Francis Sean Moolman
Heidi Rolfes
Der Merwe Philo Lothar Van
Original Assignee
Csir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25589180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ITMI20021169(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Csir filed Critical Csir
Publication of ITMI20021169A0 publication Critical patent/ITMI20021169A0/it
Publication of ITMI20021169A1 publication Critical patent/ITMI20021169A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Medicinal Preparation (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Paints Or Removers (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IT2002MI001169A 2001-05-30 2002-05-30 Procedimento per incapsulare una sostanza attiva ITMI20021169A1 (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ZA200104451 2001-05-30

Publications (2)

Publication Number Publication Date
ITMI20021169A0 ITMI20021169A0 (it) 2002-05-30
ITMI20021169A1 true ITMI20021169A1 (it) 2003-12-01

Family

ID=25589180

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2002MI001169A ITMI20021169A1 (it) 2001-05-30 2002-05-30 Procedimento per incapsulare una sostanza attiva

Country Status (21)

Country Link
US (1) US7641917B2 (it)
EP (1) EP1401404B1 (it)
JP (1) JP4313196B2 (it)
CN (1) CN1255099C (it)
AT (1) ATE392203T1 (it)
AU (1) AU2002310567B2 (it)
BR (1) BR0210000A (it)
CA (1) CA2455208C (it)
CH (1) CH695418A5 (it)
CY (1) CY1108199T1 (it)
DE (2) DE10296849T5 (it)
DK (1) DK1401404T3 (it)
ES (1) ES2305250T3 (it)
FR (1) FR2825292B1 (it)
GB (1) GB2392619B (it)
HK (1) HK1066488A1 (it)
IT (1) ITMI20021169A1 (it)
NL (1) NL1020706C2 (it)
PT (1) PT1401404E (it)
WO (1) WO2003013478A2 (it)
ZA (1) ZA200309983B (it)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1401404B1 (en) 2001-05-30 2008-04-16 Csir Method of encapsulating an active substance
US7903319B2 (en) * 2006-07-11 2011-03-08 E Ink Corporation Electrophoretic medium and display with improved image stability
US20080082764A1 (en) * 2006-10-03 2008-04-03 Yi Feng Jang Memory accessing system and method
GB0812742D0 (en) 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
GB201317756D0 (en) 2013-10-08 2013-11-20 Critical Pharmaceuticals Ltd New process
DE102018210030A1 (de) * 2018-06-20 2019-12-24 Thyssenkrupp Ag Verwendung und Recyclieren von überkritischen CO2 als Lösungsmittel für PLA und weitere biologisch abbaubaren Polymere in das Beschichtungsverfahren für Düngemittel
IT201800007993A1 (it) * 2018-08-09 2020-02-09 Greenbone Ortho Srl Impianto finalizzato alla trasformazione chimica di materiali nello stato 3d
CN112812355B (zh) * 2020-12-31 2022-09-23 厦门天生爱科技有限公司 一种具有缓释挥发性中草药有效成分的功能高分子发泡材料、制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8500121D0 (en) 1985-01-03 1985-02-13 Connaught Lab Microencapsulation of living cells
EP0321607B1 (en) * 1987-12-21 1993-09-22 Union Carbide Corporation Supercritical fluids as diluents in liquid spray application of coatings
EP0706821A1 (en) * 1994-10-06 1996-04-17 Centre De Microencapsulation Method of coating particles
US5939485A (en) * 1995-06-19 1999-08-17 Medlogic Global Corporation Responsive polymer networks and methods of their use
WO1997006787A2 (en) * 1995-08-17 1997-02-27 Dyer, Alison, Margaret Controlled release products
FR2753639B1 (fr) * 1996-09-25 1998-12-11 Procede de preparation de microcapsules de matieres actives enrobees par un polymere et nouvelles microcapsules notamment obtenues selon le procede
US5766637A (en) * 1996-10-08 1998-06-16 University Of Delaware Microencapsulation process using supercritical fluids
JP3770917B2 (ja) * 1997-02-17 2006-04-26 株式会社ドペル 人造石の製造方法
GB9800936D0 (en) 1997-05-10 1998-03-11 Univ Nottingham Biofunctional polymers
ES2342747T3 (es) 1997-10-15 2010-07-13 University Of South Florida Recubrimiento de material en particulas asistido por un fluido supercritico.
IT1296464B1 (it) * 1997-11-19 1999-06-25 Vectorpharma Int Composizioni farmaceutiche in forma di polveri di polimeri reticolati caricati con farmaci e relativo processo di preparazione mediante
GB9814619D0 (en) 1998-07-06 1998-09-02 Cole Polytechnique Fudurale De Materials and methods relating to encapsulation
US6340722B1 (en) 1998-09-04 2002-01-22 The University Of Akron Polymerization, compatibilized blending, and particle size control of powder coatings in a supercritical fluid
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
GB9920558D0 (en) * 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
US6372259B1 (en) * 1999-11-10 2002-04-16 University Of Iowa Research Foundation Palatable, sustained release drug granules
US6521258B1 (en) * 2000-09-08 2003-02-18 Ferro Corporation Polymer matrices prepared by supercritical fluid processing techniques
AU2001285242A1 (en) 2000-09-08 2002-03-22 Ferro Corporation Controlled-release pharmaceuticals prepared by supercritical fluid processing techniques
EP1401404B1 (en) 2001-05-30 2008-04-16 Csir Method of encapsulating an active substance

Also Published As

Publication number Publication date
GB2392619B (en) 2004-10-20
ZA200309983B (en) 2005-01-26
EP1401404B1 (en) 2008-04-16
DE10296849T5 (de) 2004-04-29
FR2825292B1 (fr) 2006-06-09
US7641917B2 (en) 2010-01-05
US20050112205A1 (en) 2005-05-26
NL1020706A1 (nl) 2002-12-03
CN1512877A (zh) 2004-07-14
JP4313196B2 (ja) 2009-08-12
JP2005502642A (ja) 2005-01-27
ATE392203T1 (de) 2008-05-15
HK1066488A1 (en) 2005-03-24
DE60226140T2 (de) 2009-05-07
CA2455208A1 (en) 2003-02-20
DK1401404T3 (da) 2008-08-11
CH695418A5 (de) 2006-05-15
ES2305250T3 (es) 2008-11-01
WO2003013478A8 (en) 2003-04-03
CN1255099C (zh) 2006-05-10
GB2392619A (en) 2004-03-10
EP1401404A2 (en) 2004-03-31
WO2003013478A2 (en) 2003-02-20
ITMI20021169A0 (it) 2002-05-30
BR0210000A (pt) 2004-05-04
GB0327381D0 (en) 2003-12-31
DE60226140D1 (de) 2008-05-29
FR2825292A1 (fr) 2002-12-06
CA2455208C (en) 2009-02-03
WO2003013478A3 (en) 2003-05-30
CY1108199T1 (el) 2014-02-12
PT1401404E (pt) 2008-07-23
NL1020706C2 (nl) 2003-04-28
AU2002310567B2 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
WO2002013786A3 (en) Method of forming microparticles
WO2005098083A3 (en) Miniature microwave plasma torch application and method of use thereof
WO2002060573A3 (de) Kapseln-in-kapsel-system und verfahren zu seiner herstellung
ES2138085T3 (es) Xinafoato de salmeterol con tamaño de particula controlado.
CA2327522A1 (en) Incorporation of active substances in carrier matrixes
WO2002049619A3 (en) Induced phase transition method for the production of microparticles containing hydrophilic active agents
DK1180062T3 (da) Fremgangsmåde til fremstilling af morfologisk ensartede mikro- og nanopartikler ved hjælp af en anordning til mikroblanding
WO2004058943A3 (en) Device and process for the preparation of autologous thrombin serum
WO2002043702A3 (en) Pharmaceutical compositions for inhalation
IL159475A0 (en) Spherical protein particles, compositions containing the same and methods for the production thereof
WO2004058218A3 (en) Prefilming atomizer
EP1438421A4 (en) PRODUCTS CONTAINING FIXED QUANTITY OF BIOPARTICLES AND PROCESS FOR PRODUCING SAID PRODUCTS
ITMO20020204A1 (it) Recipiente per la confezione di prodotti fluidi o pastosi, particolarmente cosmetici, medicinali e simili
ITMI20021169A1 (it) Procedimento per incapsulare una sostanza attiva
AU2001291647A1 (en) Coated particles containing an active substance
HUP0303006A3 (en) Retinoids for the treatment of emphysema, process for their preparation and pharmaceutical compositions containing them
MXPA03007635A (es) P-tienilbencilamidas que sirven como agonistas de receptores para angiotensina-(1-7), metodo para su produccion, su uso y preparaciones farmaceuticas que las contienen.
DE60103865D1 (de) Arzneizubereitungen und deren herstellungsverfahren
DE69932182D1 (de) Präparationen, die virus-ähnliche partikel als immunpotentiatoren enthalten und durch die schleimhaut verabreicht werden.
BRPI0507765A (pt) comprimidos revestidos compressos e sua produção
BR0207630A (pt) Processo para a preparação de compostos de inclusão entre um fármaco e ciclodextrina por meio de tratamento com microondas
WO2003031319A3 (de) Adhäsionsverminderte mikromechanische bauelemente
IT1320897B1 (it) Metodo e relativo impianto per lo scarico di prodotti fragili
CA2408753A1 (en) The wet presentation and sorting of particles
FR2829939B3 (fr) Utilisation du 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5- dihydro-4h-pyridazino(4,5-b)indole-1-acetamide pour la preparation de medicaments destines au traitement de la polyarthrite rhumatoide